{"id":"W2002307343","doi":"10.1517/13543784.2011.549125","title":"AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Amgen (Canada)","funders":"","keywords":"Angiopoietin 2; Ovarian cancer; Medicine; Angiogenesis; Malignancy; Cancer; Oncology; Antagonist; Internal medicine; Disease; Tumor progression; Overall survival; Cancer research; Receptor; VEGF receptors; Vascular endothelial growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002834993,0.0001594377,0.0003834742,0.0001580931,0.00007668117,0.0002988797,0.0001346725,0.0002654542,0.002523796],"category_scores_gemma":[0.0005654775,0.00004156502,0.0002374093,0.0002124356,0.00005837666,0.0001862146,0.0001090751,0.0005049136,0.0004741803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002162991,"about_ca_system_score_gemma":0.0002405479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001945857,"about_ca_topic_score_gemma":0.00070241,"domain_scores_codex":[0.9999081,0.00002781902,0.000009532707,0.00001392622,0.00002780019,0.00001290678],"domain_scores_gemma":[0.9998642,0.00004183979,0.00004135735,0.00000257367,0.00002527341,0.0000247386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006183188,0.0002781643,0.01100314,0.00357144,0.0004612062,0.0006846666,0.0001168473,0.001070359,0.03310287,0.0009409265,0.01947145,0.9231157],"study_design_scores_gemma":[0.006520397,0.04152134,0.1094201,0.003253761,0.002654071,0.01330229,0.000333749,0.003505016,0.02481655,0.003455224,0.7911133,0.0001042655],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2230813,0.7505119,0.001409532,0.004514213,0.000523811,0.0002495646,0.001426592,0.00009793392,0.01818512],"genre_scores_gemma":[0.7009467,0.2798055,0.003116535,0.005023862,0.0008484905,0.0002798121,0.002774592,0.00003132377,0.007173276],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002523796,"threshold_uncertainty_score":0.008442998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0426732515451642,"score_gpt":0.3193840067145453,"score_spread":0.276710755169381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}